HC Wainwright Downgrades Traws Pharma to Hold
HC Wainwright has revised its outlook on Traws Pharma, lowering the rating to hold.
Key Points
- HC Wainwright downgraded Traws Pharma to a hold rating with a new price target of $1.0 on June 18, 2026.
- Shares of NasdaqCM:TRAW are trading around $0.80, with a market cap of approximately $12.9 million.
- Peer funds like Dauntless Investment Group added 416,998 shares, while Squadron Capital reduced their holdings by 201,826 shares.
HC Wainwright has adjusted its stance on Traws Pharma, Inc. (NasdaqCM: TRAW) by downgrading the stock to a hold rating and setting a price target of $1.0. This change was announced on June 18, 2026, amid a backdrop of fluctuating share prices and market conditions.
Other Institutional Activity in Traws Pharma
Several institutional investors have been active in Traws Pharma. Dauntless Investment Group added 416,998 shares, bringing its total to 416,998 shares valued at approximately $763,106. Meanwhile, Squadron Capital Management trimmed its holdings by 201,826 shares, leaving it with 511,714 shares worth about $936,437. Other investors, such as Adage Capital Partners and Ikarian Capital, maintained their positions without any changes.
Traws Pharma Stock Snapshot
Shares of NasdaqCM:TRAW are currently trading near $0.80. Traws Pharma has a market capitalization of about $12.9 million. The stock's 52-week range has seen a low of $0.64 and a high of $3.27. The company has a 50-day moving average of $1.43 and a 200-day moving average of $1.87. With a current ratio of 0.429 and a quick ratio of 0.365, the company faces liquidity challenges.
Insider Buying and Selling at Traws Pharma, Inc.
Insiders at Traws Pharma have been active as well. On April 16, 2026, OrbiMed Advisors LLC made multiple purchases, including one of 597,729 shares at an average price of $1.67. Earlier in the year, on March 8, 2026, Chief Financial Officer Parker Charles Nolan acquired 104,544 shares.
Analysts Set New Price Targets
On June 18, 2026, HC Wainwright & Co. downgraded Traws Pharma to a hold rating with a $1.0 price target. Previously, on May 20, 2026, the firm reiterated a buy rating with a much higher target of $8.0. As of now, the consensus recommendation is a buy, with a mean target price of $8.0 based on one analyst opinion.
About Traws Pharma
Traws Pharma, Inc., based in Newtown, Pennsylvania, is a clinical-stage biopharmaceutical company specializing in small synthetic molecules for respiratory viral diseases and cancer. The company is developing treatments for conditions like COVID-19 and influenza, including TRX01 and Tivoxavir marboxil. Traws Pharma also focuses on cancer therapies such as narazaciclib and rigosertib. Led by CEO Dr. Iain D. Dukes, the company employs four people.
Bottom Line
The downgrade by HC Wainwright reflects a more cautious outlook on Traws Pharma, which faces ongoing challenges in a competitive biotech sector. Investors keep a close watch on analyst ratings and institutional activity to gauge market sentiment. It's important to remember that these ratings are based on past performance and market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.